Scalable Terbium-149 Production from Highly Enriched Gadolinium-150 Targets
En palabras de los autores
We propose a two-stage production method to overcome existing supply-constraints for the alpha-emitter Tb, a promising candidate for Targeted Alpha Therapy (TAT) with no existing globally scalable production pathway. Although awaiting experimental measurement of the Gd(p,2n)Tb cross section, the proposed method could produce Tb at clinical scale and beyond on readily available proton cyclotrons, enabled by production of the extinct but long-lived isotope Gd, a pure alpha emitter with a 1.79 million year half-life. Stage one generates Gd feedstock by irradiating natural Eu or enriched Eu with 10 MeV protons, neutrons or photons. Stage two produces Tb from fabricated Gd targets by driving the Gd(p,2n)Tb reaction with 14 MeV protons, accessible on over 700 reported cyclotrons worldwide. Fast fusion neutrons appear to offer the most scalable pathway for Gd production: even with a large Tb dose size of 1 GBq and 40 million administered doses/yr, we estimate this would require neutrons produced by only 6.8 megawatts of steady-state deuterium-tritium power to produce the required Gd, far below expected capacity in the next decade. The route described here, if validated, would enable Tb supply at the scale needed to support clinical development of Tb-based TAT.
Apareció: miércoles, 23 de septiembre. arXiv. Preprint, todavía sin revisión por pares.
Comentario de los autores: 61 pages, 25 figures